# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Vance-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Start of letrozole, ribociclib, and zoledronic acid after radiation. **S**

## History of present illness

Ms. Carson completed whole-breast and regional nodal radiation with a tumor-bed boost two and a half weeks ago, in 19 afternoon sessions, with mild reddening of the skin that has faded. She kept writing in the mornings throughout. Her dental check last week was normal. Today she starts letrozole and the first 28-day cycle of ribociclib, and has her first zoledronic acid infusion. She has read the side-effect sheets and asked for the monitoring schedule in writing, which she was given. She has mild morning knee stiffness, unchanged, and no hot flashes. She takes no other medicines and no grapefruit or herbal products. **S**

| Element | Detail |
|---|---|
| Interval change | Radiation completed two and a half weeks ago |
| Skin | Grade 1 reddening, now faded |
| Today | Letrozole and ribociclib cycle 1 day 1; first zoledronic acid infusion |
| Dental | Dental check last week normal |
| Interactions | No QT-prolonging drugs, strong CYP3A inhibitors, grapefruit, or herbal products |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild tiredness after radiation, improving |
| Integumentary | Negative | Radiation reddening faded; no blistering |
| Cardiovascular | Negative | No palpitations, fainting, or chest pain |
| Musculoskeletal | Positive | Mild morning knee stiffness, baseline before letrozole; no bone pain |
| Genitourinary | Negative | No vaginal dryness or bleeding |
| Psychiatric | Negative | Mood steady |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day **S**
- Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**
- Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years **S**
- Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 58.9 kg; BMI 22.2 kg/m². All vital signs are synthetic.

Hemoglobin: 12.8 g/dL; White cell count: 5.9 10*3/uL; Absolute neutrophil count: 3.4 10*3/uL; Platelets: 240 10*3/uL; Creatinine: 0.8 mg/dL; eGFR: 87 mL/min/1.73 m²; ALT: 20 U/L; AST: 22 U/L; Total bilirubin: 0.6 mg/dL; Potassium: 4.2 mmol/L; Magnesium: 2.1 mg/dL; Calcium: 9.4 mg/dL; Total cholesterol: 208 mg/dL (high); HDL cholesterol: 62 mg/dL; LDL cholesterol: 124 mg/dL (high); Triglycerides: 110 mg/dL; 25-hydroxyvitamin D: 22 ng/mL (low); QTc (ECG): 418 ms; Lumbar spine T-score (DXA): -1.8 (low); Femoral neck T-score (DXA): -1.3 (low). All results are synthetic.

## Change since baseline

- Hemoglobin: 12.3 g/dL at baseline, 12.8 g/dL at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 5.9 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 240 10*3/uL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 20 U/L at this visit **S**
- AST: 20 U/L at baseline, 22 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Breasts | Left breast with faint tanning and mild firmness after radiation; scar healed; no masses. Right breast normal |
| Lymph nodes | No axillary or supraclavicular nodes |
| Extremities | Arm circumference 25.5 cm on each side; full shoulder movement; knees with mild crepitus, no effusion |
| Mouth | Teeth and gums in good repair |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Letrozole with ribociclib, starting today** (Z79.811). Baseline QTcF 418 ms, below the 450 ms limit for starting ribociclib. Neutrophils 3.4, liver tests normal, potassium 4.2, magnesium 2.1, calcium 9.4. No interacting drugs. **S**
   - Letrozole 2.5 mg daily.
   - Ribociclib 400 mg on days 1 to 21 of each 28-day cycle.
   - ECG at about day 14; blood count and liver tests every two weeks for two cycles, then at the start of the next four cycles; electrolytes at the start of each of the first six cycles.
   - Fever of 38.0 °C or more, palpitations, fainting, yellow eyes, or dark urine to be reported the same day.
2. **Low bone mass on baseline DXA, with vitamin D insufficiency** (M85.80). Lumbar spine T-score -1.8, femoral neck -1.3; 10-year major fracture risk about 7 percent. Letrozole speeds bone loss; the adjuvant zoledronic acid she chose also protects bone. Vitamin D 22 ng/mL, creatinine 0.8, eGFR 87, calcium normal. **S**
   - Zoledronic acid 4 mg intravenously today, then every six months for three years.
   - Vitamin D3 1000 units daily and calcium from food.
   - Weight-bearing and strength exercise.
   - Repeat DXA in two years.
3. **Knee osteoarthritis** (M17.0). Mild and stable; recorded as the baseline before letrozole, which can cause joint aches. **S**
   - Walking and quadriceps exercises; acetaminophen as needed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | ECG before ribociclib | Before the first dose; start only if QTcF is below 450 ms | Completed today | QTcF 418 ms, sinus rhythm 70/min |
| Laboratory | Blood count before ribociclib | Before the first dose, then every 2 weeks for 2 cycles | Completed today | White cells 5.9, neutrophils 3.4, hemoglobin 12.8, platelets 240 |
| Laboratory | Liver tests before ribociclib | Before the first dose, then every 2 weeks for 2 cycles | Completed today | ALT 20, AST 22, bilirubin 0.6 |
| Laboratory | Electrolytes before ribociclib | Before the first dose and at the start of each of the first 6 cycles | Completed today | Potassium 4.2, magnesium 2.1, calcium 9.4 |
| Medication safety | Interaction review: QT-prolonging drugs and strong CYP3A inhibitors | At the start and with every new medicine | Completed today | None taken; written list given |
| Medication safety | ECG at about day 14 of the first cycle | Day 14 of cycle 1 | Due | Booked with the day-14 blood tests |
| Medication safety | Aromatase inhibitor start | At initiation | Completed today | Letrozole 2.5 mg daily; postmenopausal for two years, so no ovarian suppression needed |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start, then every 2 years | Completed today | Lumbar spine T-score -1.8, femoral neck -1.3: low bone mass |
| Medication safety | Zoledronic acid: kidney function, calcium, and dental check | Before each infusion | Completed today | Creatinine 0.8, eGFR 87, calcium 9.4; dental check normal; first infusion today |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 22 ng/mL, insufficient; vitamin D3 started |
| Laboratory | Lipid panel | Periodically on an aromatase inhibitor, by cardiovascular risk | Completed today | Total cholesterol 208, HDL 62, LDL 124, triglycerides 110 mg/dL |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Baseline: mild knee stiffness from osteoarthritis |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side; no swelling after nodal radiation |
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No signs of recurrence |
| Imaging | Mammogram after breast-conserving treatment | 6 to 12 months after radiation, then yearly | Due | Between six and twelve months after radiation |
| Self-management | Written monitoring schedule and survivorship care plan | At the start of adjuvant therapy | Completed today | Monitoring calendar and treatment summary given; 150 minutes of activity a week; alcohol at or below one drink a day |

## Goal progress

- Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report. Outcome by 2026-03-18: Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding. **S**
- Make each treatment decision herself after hearing the options, benefits, and harms. Outcome by 2026-04-20: Chose breast-conserving surgery and, after the pathology, radiation, letrozole, ribociclib, and zoledronic acid. **S**
- Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis. Outcome by 2026-06-15: Lumpectomy at three weeks, radiation completed at ten weeks, letrozole and ribociclib started at thirteen weeks. **S**
- Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule. In progress; target 2026-12-07. **S**
- Keep writing at least four mornings a week through treatment. In progress; target 2026-12-07. **S**

## Medication changes

- Started: Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**
- Started: Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years **S**
- Started: Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years **S**
- Started: Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024), American Society of Clinical Oncology
- KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026), U.S. National Library of Medicine, DailyMed
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022), American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Oncology ECG and blood tests at about day 14. Sick visits through the oncology nurse line for fever. Primary care monitoring visit at the start of the fourth cycle. **S**
- Next scheduled visit 2026-09-08: monitoring visit at the start of the fourth ribociclib cycle. **S**
